Our innovative approach focuses on the development of a diverse array of next-generation protein therapeutics including Pronectin™ cancer immunotherapies, Pronectin™ drug conjugates (PDCs), T-cell engaging Pronectin™ and bi-specific and Pronectin™, enabled chimeric antigen receptor (Pn-CAR-T ™) cell therapies.
Antibody therapeutics have revolutionized the treatment of a number of diseases including cancer and inflammation. There are more than 470 antibody therapeutics in clinical testing which is a testimony to the applications of antibody engineering that have played a major role in expanding this family of large molecule therapeutics over the past two decades. Several antibodies have now reached FDA approval and commercialization including: function blocking antibodies that target cancer cell surface receptors (e.g. anti-HER2, anti-EGFR, anti-CD2 and anti-PDL1 antibodies); Antibody-Drug Conjugates (ADCs) (e.g.: Kadcyla®, Adcetris®) and Bi-specific ADCs; Immune-check point T-cell modulators (anti-PD1 or anti-CTLA4 antibodies); Bi-specific T-cell Engagers (BITE®), Immune mobilizing monoclonal TCRs Against Cancer (ImmTACs) that recruit and activate T-cells; Engineered T-cells with Chimeric Antigen Receptors (CARs) (anti-CD19 CARs). Very recently, Novartis CAR-T cell therapy CTL019 was unanimously recommended for approval by FDA advisory committee to treat pediatric, young adult B-cell leukemia.
Our Pronectin™ technology and drug discovery platform that can be exploited to replace many antibody therapeutic modalities as highlighted below.
Each of these therapeutic modalities have shown incredible potential and the opportunity to bring forth new options for better drugs in multiple ways including more selective targeting and improved manufacturability.
1 & 8. Pronectin™ Bi-specific T-cell Engagers (Pn-BITE™), 2. Fc-Pronectin™, 3. Pronectin™ engineered Chimeric Antigen Receptor T-Cells (Pn-CAR-T™), 4. Function blocking Pronectins™ that target cancer cell surface receptors, 5. Pronectin-Drug Conjugates (PnDC™), 6. Immune-check point Pronectin™ T-cell modulators, 7. Pronectin Bi-specific Drug Conjugates (PnDC™).
